Skip to main content
69°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
191.78
-6.72 (-3.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
7 Biotech Stocks to Buy for Big-Time Gains
November 10, 2023
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Via
InvestorPlace
Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
September 21, 2023
Via
Benzinga
The Latest Analyst Ratings for BeiGene
September 12, 2023
Via
Benzinga
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
BeiGene, Ltd.
Via
Business Wire
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session
November 06, 2023
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
October 30, 2023
Gainers
Via
Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data
October 18, 2023
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR)
Via
Benzinga
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
October 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
October 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
October 13, 2023
From
BeiGene
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
October 02, 2023
Via
Benzinga
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...
Via
Talk Markets
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 20, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.
Via
Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
September 19, 2023
Bloomberg
Via
Benzinga
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
September 19, 2023
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS).
Via
Benzinga
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023
From
BeiGene, Ltd.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
September 12, 2023
Via
Benzinga
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
September 11, 2023
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 11, 2023
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...
Via
Benzinga
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023
From
BeiGene
Via
Business Wire
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
August 29, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.